Mingchen HealthLtd (SZSE:002919) Jumps 12% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
Mingchen HealthLtd (SZSE:002919) Jumps 12% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking involves risks (and requires diversification) it can also provide excess returns. For example, the Mingchen Health Co.,Ltd. (SZSE:002919) share price is up 63% in the last 5 years, clearly besting the market decline of around 9.4% (ignoring dividends).
當我們進行投資時,通常尋找的是超過市場平均水平的股票。儘管積極的選擇股票涉及風險(並需要分散風險),但它也可以提供超額回報。例如,名臣健康股份有限公司(SZSE:002919)的股價在過去5年中上漲了63%,顯然超過了市場下跌的9.4%(不包括股息)。
Since it's been a strong week for Mingchen HealthLtd shareholders, let's have a look at trend of the longer term fundamentals.
由於這對名臣健康股份有限公司的股東來說是一個強勁的一週,讓我們來看一下長期基本面的趨勢。
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
雖然市場是一個強大的定價機制,但股價反映的不僅僅是企業的基本業績,還有投資者的情緒。一個不完美但簡單的方式來考慮公司市場意識的變化是比較每股收益(EPS)的變化和股價的變化。
Over half a decade, Mingchen HealthLtd managed to grow its earnings per share at 6.0% a year. This EPS growth is lower than the 10% average annual increase in the share price. This suggests that market participants hold the company in higher regard, these days. And that's hardly shocking given the track record of growth. This optimism is visible in its fairly high P/E ratio of 108.51.
在過去的五年中,名臣健康股份有限公司成功地實現了每股收益以年均6.0%的速度增長。這種每股收益增長的速度低於股價每年平均增長10%。這表明現在市場參與者更看好該公司。考慮到增長的歷史記錄,這並不奇怪。這種樂觀情緒在其相對較高的市盈率(108.51)中可見一斑。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
該公司的每股收益(隨時間的推移)如下圖所示(單擊可查看確切數字)。

It might be well worthwhile taking a look at our free report on Mingchen HealthLtd's earnings, revenue and cash flow.
值得一看我們對名臣健康有關盈利、營業收入和現金流的免費報告
What About Dividends?
那麼分紅怎麼樣呢?
It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. We note that for Mingchen HealthLtd the TSR over the last 5 years was 69%, which is better than the share price return mentioned above. And there's no prize for guessing that the dividend payments largely explain the divergence!
對於任何給定的股票來說,考慮總股東回報和股價回報是很重要的。TSR包括任何拆分或折價增資的價值,以及任何分紅,基於分紅再投資的假設。所以對於支付豐厚股息的公司來說,TSR往往比股價回報高得多。我們注意到,過去5年名臣健康的TSR爲69%,優於上述股價回報。猜測分紅支付很大程度上解釋了這種分歧!
A Different Perspective
不同的觀點
We regret to report that Mingchen HealthLtd shareholders are down 53% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 20%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. On the bright side, long term shareholders have made money, with a gain of 11% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand Mingchen HealthLtd better, we need to consider many other factors. Case in point: We've spotted 4 warning signs for Mingchen HealthLtd you should be aware of, and 1 of them is significant.
我們遺憾地報告說,名臣健康股東今年持有的股份下跌了53%(即使包括分紅派息在內)。不幸的是,這比更廣泛的市場下跌20%要糟糕。 話雖如此,不可避免地,在市場下跌時會有一些股票被過度拋售。關鍵在於關注基本發展。 光明面是,長期股東已經賺錢,五年內每年增長11%。最近的拋售可能是一個機會,因此值得檢查基本數據,看看是否有長期增長趨勢的跡象。 跟蹤股價表現的長期發展總是很有趣。但要更好地了解名臣健康,我們需要考慮許多其他因素。 舉個例子:我們發現了名臣健康存在4個警告信號,您應該注意,其中1個很重要。
But note: Mingchen HealthLtd may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但請注意:名臣健康有限公司可能不是最好的股票買入選擇。因此,請查看下面這個有過去盈利增長(以及預計進一步增長)的有趣公司的免費名單。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。